Ignite Creation Date:
2024-05-05 @ 11:41 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00103844
Status:
COMPLETED
Last Update Posted:
2010-08-10
First Post:
2005-02-15
Brief Title:
Dasatinib BMS-354835 Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
A Randomized Multi-Center Open Label Study of BMS-354825 vs Imatinib Mesylate Gleevec 800 mgd in Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease That is Resistant to Imatinib at a Dose at 400 - 600 mgd
Status:
COMPLETED
Status Verified Date:
2010-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of this study is to estimate the major cytogenetic response rates of BMS-354825 and imatinib 800 mgd in subjects with chronic phase Philadelphia chromosome positive chronic myeloid leukemia PH CML with disease resistant to imatinib at a dose of 400-600 mgd
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None